This result agrees with the literature and with clinicians’ claims who advise the tested patients of having a genetic mutation or a variant in the RAD51D gene, which is likely pathogenic and was associated with an increased chance to develop numerous diseases, including breast and ovarian cancers [57]. This evidence concerns the gene RAD51D and ovarian cancer.